Bridging the gap: Bitopic ligands of G-protein-coupled receptors

Trends in Pharmacological Sciences

Volumn 34, Issue 1, 2013, Pages 59-66

  Lane, J Robert ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

(2 AMINO 4,5 DIMETHYL 3 THIENYL) [3 [TRIFLUOROMETHYL]PHENYL]METHANONE; 1 [1' [2 METHYLBENZYL] 1,4'BIPIPERIDIN 4 YL] 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1 [3 [BUTYL 1 PIPERIDINYL]PROPYL] 3,4 DIHYDRO 2(1H)QUINOLINONE; 3 BENZHYDRYL PYRROLIDINE; 4 AMINOBENYLPEPERIDINE; 4 N BUTYL 1 [4 [2 METHYLPHENYL] 4 OXO 1 BUTYL]PIPERIDINE HYDROCHLORIDE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; AC 42; ADENOSINE RECEPTOR AFFECTING AGENT; BITOPIC LIGAND; CHOLINERGIC RECEPTOR AFFECTING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND; LUF 6258; PYRROLIDINE DERIVATIVE; THRX 160209; UNCLASSIFIED DRUG;

BINDING SITE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

DRUG DISCOVERY; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84871806221     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.10.003     Document Type: Review

References (55)

1. M. Congreve Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 54 2011 4283 4311
2. M.C. Lagerström, and H.B. Schiöth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discov. 7 2008 339 357
3. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
4. K. Leach Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 28 2007 382 389
5. L.T. May Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 47 2007 1 51
6. E. Jacoby The 7 TM G-protein-coupled receptor target family ChemMedChem 1 2006 761 782
7. K. Mohr Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 159 2010 997 1008
8. J. Antony Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 23 2009 442 450
9. T. Disingrini Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J. Med. Chem. 49 2006 366 372
10. C. Valant A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J. Biol. Chem. 283 2008 29312 29321
11. C. Valant Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs Mol. Interv. 9 2009 125 135
12. T. Steinfeld THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner Mol. Pharmacol. 79 2011 389 399
13. 2 muscarinic receptor Mol. Pharmacol. 72 2007 291 302
14. 1 receptor J. Med. Chem. 53 2010 3028 3037
15. B.K. Kobilka, and X. Deupi Conformational complexity of G-protein-coupled receptors Trends Pharmacol. Sci. 28 2007 397 406
16. S.G.F. Rasmussen Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 477 2011 549 555
17. V. Cherezov High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 318 2007 1258 1265
18. V. Katritch Diversity and modularity of G protein-coupled receptor structures Trends Pharmacol. Sci. 33 2012 17 27
19. W. Stallaert Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors Expert Opin. Drug Discov. 6 2011 811 825
20. C. Koole Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening Mol. Pharmacol. 78 2010 456 465
21. K. Leach Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 35 2010 855 869
22. T. Kenakin A simple method for quantifying functional selectivity and agonist bias ACS Chem. Neurosci. 3 2012 193 203
23. P.S. Portoghese From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 44 2001 2259 2269
24. T. Spalding Identification of a ligand-dependent switch within a muscarinic receptor J. Biol. Chem. 273 1998 21563 21568
25. C.J. Langmead Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 154 2008 1104 1115
26. C.K. Jones Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28 2008 10422 10433
27. 1 receptor: direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 69 2006 236 246
28. 1 muscarinic acetylcholine receptor Mol. Pharmacol. 78 2010 94 104
29. 1 muscarinic receptor allosteric agonists AC-42 and 1-[1″-(2-methylbenzyl)-1,4″-bipiperidin-4-yl]-1,3-dihydro- 2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site Mol. Pharmacol. 78 2010 648 657
30. 1 muscarinic acetylcholine receptors Mol. Pharmacol. 75 2009 331 341
31. T.W. Schwartz, and B. Holst Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol. Sci. 28 2007 366 373
32. A. Kebig An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators J. Recept. Signal Transduct. Res. 29 2009 140 145
33. M. De Amici Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med. Res. Rev. 30 2010 463 549
34. K.J. Gregory Allosteric modulation of muscarinic acetylcholine receptors Curr. Neuropharmacol. 5 2007 157 167
35. 2A adenosine receptor bound to an antagonist Science 322 2008 1211 1217
36. 3 selective antagonist Science 330 2010 1091 1095
37. 1 receptor complex with doxepin Nature 475 2011 65 70
38. H. Wu Structure of the human κ-opioid receptor in complex with JDTic Nature 485 2012 327 332
39. B. Wu Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
40. S. Granier Structure of the δ-opioid receptor bound to naltrindole Nature 485 2012 400 404
41. A. Manglik Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 485 2012 321 326
42. 2-adrenergic receptor ligands Proc. Natl. Acad. Sci. U.S.A. 106 2009 6843 6848
43. 3 receptor homology model and crystal structure Nat. Chem. Biol. 7 2011 769 778
44. 2A adenosine receptor ligands J. Med. Chem. 53 2010 3748 3755
45. A. Ivetac, and J.A. McCammon Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach Chem. Biol. Drug Des. 76 2010 201 217
46. R.O. Dror Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U.S.A. 108 2011 13118 13123
47. G. Andrews An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5 Mol. Pharmacol. 73 2008 855 867
48. B. Ma Dynamic allostery: linkers are not merely flexible Structure 19 2011 907 917
49. M. Mammen Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Angew. Chem. Int. Ed. 37 1998 2754 2794
50. J. Shonberg Design strategies for bivalent ligands targeting GPCRs ChemMedChem 6 2011 963 974
51. C. Valant The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 52 2012 153 178
52. R. Morphy From magic bullets to designed multiple ligands Drug Discov. Today 9 2004 641 651
53. 2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J. Biol. Chem. 285 2010 7459 7474
54. M. Petrek CAVER: a new tool to explore routes from protein clefts, pockets and cavities BMC Bioinform. 7 2006 316
55. 2 muscarinic acetylcholine receptor bound to an antagonist Nature 482 2012 547 551